Evidence map›Paper›PMID 36326273›Full record

ArticleJournal of virology2022

Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele.

Yu Zhang, Takayuki Chikata, Nozomi Kuse, Hayato Murakoshi, Hiroyuki Gatanaga, Shinichi Oka, Masafumi Takiguchi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yu ZhangDivision of International Collaboration Research and Tokyo Joint Laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.
Takayuki ChikataDivision of International Collaboration Research and Tokyo Joint Laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.
Nozomi KuseDivision of International Collaboration Research and Tokyo Joint Laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.
Hayato MurakoshiDivision of International Collaboration Research and Tokyo Joint Laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.
Hiroyuki GatanagaAIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Shinichi OkaAIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Masafumi TakiguchiDivision of International Collaboration Research and Tokyo Joint Laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.ORCID 0000-0002-8516-6442
Kumamoto University · JPNational Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare HLA alleles such as HLA-B57 are associated with slow progression to AIDS. However, the evidence for the advantage of rare protective alleles is limited, and the mechanism is still unclear. Although the prevalence of HLA-B*67:01 is only 1.2% in Japan, HLA-B*67:01-positive (HLA-B*67:01

Indexed as

HIV-1HIV InfectionsHIV SeropositivityAllelesCD8-Positive T-LymphocytesDisease ProgressionEpitopesEpitopes, T-LymphocyteHLA-B AntigensHumansVirus ReplicationEpitopesEpitopes, T-LymphocyteHLA-B AntigensCD8+ T cellsHIV-1HLA-B*67:01protective epitope

Identifiers

PMID36326273
PMCPMC9683060
OpenAlexW4308057179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.